Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recordati SpAMIL:REC -0.67%94 3-Year EPS without NRI Growth Rate is 10.70% as of Jun. 2026, which is 4% below its 10-year median of 11.15. GuruFocus rates MIL:REC with a GF Score™ of 94/100 and a GF Value™ of €61.45 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 785 Drug Manufacturers companies, Recordati SpA ranks better than 52.36% on this metric.
During the past 12 months, Recordati SpA's average EPS without NRI Growth Rate was 23.40% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 10.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 5.30% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 7.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Recordati SpA was 44.90% per year. The lowest was -1.70% per year. And the median was 11.15% per year.
Recordati SpA (MIL:REC) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Recordati SpA 3-Year EPS without NRI Growth Rate Related Terms
MIL:REC vs LLY, JNJ, ABBV: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Recordati SpA's 3-Year EPS without NRI Growth Rate falls into.
Recordati SpA 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 10.70% mean?
Recordati SpA (MIL:REC) has a 3-Year EPS without NRI Growth Rate of 10.70% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Recordati SpA and its competitors. This is near median its historical median of 11.15. According to the industry distribution chart, Recordati SpA ranks #374 out of 785 companies in the Drug Manufacturers industry, placing it in the top 47.6%.
Is Recordati SpA's 3-Year EPS without NRI Growth Rate too high?
Recordati SpA's current 3-Year EPS without NRI Growth Rate of 10.70% is near median its 10-year median of 11.15. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.90. Recordati SpA's value of 10.70% is 8.1% above this industry median. Based on the distribution chart, Recordati SpA ranks #374 out of 785 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Recordati SpA has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's 3-Year EPS without NRI Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #374 out of 785 companies for 3-Year EPS without NRI Growth Rate. This puts Recordati SpA in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.90. Recordati SpA's value of 10.70% is 8.1% above this benchmark. While the company's 10-year median is 11.15 vs. the industry median of 9.90, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.90, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current 3-Year EPS without NRI Growth Rate of 10.70% is 8.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Recordati SpA and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current 3-Year EPS without NRI Growth Rate is 10.70%, which is near median its own 10-year median of 11.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €61.45, compared to a current price of €51.90 — trading 15.5% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 10.70%, which is near median its 10-year median of 11.15 and 8.1% above the Drug Manufacturers industry median of 9.90. Recordati SpA's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current 3-Year EPS without NRI Growth Rate is 10.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.90 is trading 15.5% below its estimated GF Value™ of €61.45.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
3-Year EPS without NRI Growth Rate: 10.70% (near median its 10-year median of 11.15)
GF Value™: €61.45 vs. price of €51.90 (15.5% below fair value)
Industry Position: 8.1% above the Drug Manufacturers median (#374 of 785)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
94GF Score
Get the complete analysis for MIL:REC
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
